Epidémiologie, stratégies thérapeutiques et virologie cliniques dans l'infection à VIH
Accueil
FHDH
A propos de la base
Déjà 20 ans !
DOMEVIH
Principaux résultats
- RICE février 2013
- Publications
L'équipe
- Le GEC
- U1136 (ex-U943)
Collaborations
Etudes cliniques
ONCOVIH
Autres études
EPIDERMAS
FranceCoag
Doctorants - post-docs
EPICLIN 2010

Liste des publications à partir des données
de la base FHDH

2012 2011 2010
2005-2009 2000-2004 1992-1999

2012       117  

del Amo J, Moreno S, Bucher HC, Furrer H, Logan R, Sterne J, Perez-Hoyos S, Jarrın I, Phillips A, Lodi S, van Sighem A, de Wolf F, Sabin C, Bansi L, Justice A, Goulet J, Miro JM, Ferrer E, Meyer L, Seng R, Toulomi G, Gargalianos P, Costagliola D, Abgrall S, Hernan MA and The HIV-CAUSAL Collaboration.

-->  Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries.
---->  Clin Infect Dis 2012;54:1364-72.
        118  

Cain LE, Phillips A, Lodi S, Sabin C, Bansi L, Amy Justice A, Tate J, Logan R, James M. Robins JM, Sterne JAC, van Sighem A, de Wolf F, Bucher HC, Elzi L, Touloumi G, Giorgia Vourli G, Anna EsteveA, Jordi Casabona J, Julia del Amo J, Santiago Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Abgrall S, Costagliola D, Hernán MA and the HIV-CAUSAL Collaboration.

-->  The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study.
---->  AIDS 2012;26:1691-1705.
        119  

Costagliola D, Lodwick R, Ledergerber B, Torti C, van Sighem A, Podzamczer D, Amanda Mocroft A, Dorrucci M, Masquelier B, de Luca A, Jansen K, De Wit S, Obel N, Fätkenheuer G, Touloumi G, Mussini C, Castagna A, Stephan C, García F, Zangerle R, Duval X, Perez Hoyos S, Meyer L, Ghosn J, Fabre-Colin C, Kjaer J, Chene G, Grarup J, Phillips A.

-->  Trends in virological and clinical outcomes in individuals with HIV-1 infection and virologic failure of drugs from three antiretroviral drug classes: a cohort study.
---->  Lancet Infect Dis 2012;12:119-127.
        120  

Guiguet M, Ghosn J, Duvivier C, Meynard JL, Gras G, Partisani ML, Teicher E, Mahamat A, Rodenbourg F, Launay O, Costagliola D, on behalf of the FHDH-ANRS CO4.

-->  Boosted protease inhibitor monotherapy as a maintenance strategy: an observational study in the FHDH-ANRS CO4 cohort.
---->  AIDS. 2012;26:2345-2350.
        121  

Jarrin I, Pantazis N, Gill J, Geskus R, Perez-Hoyos S, Meyer L, Prins M, Touloumi G, Johnson A, Hamouda O, García de Olalla P, Porter K, del Amo J; CASCADE Collaboration in EuroCoord.

-->  Uptake of combination antiretroviral therapy and HIV disease progression according to geographical origin in seroconverters in Europe, Canada, and Australia.
---->  Clin Infect Dis 2012;54:111-8.
        122  

Jarzebowski W, Caumes E, Dupin N, Farhi D, Lascaux AS, Piketty C, de Truchis P, Bouldouyre MA, Derradji O, Pacanowski J, Costagliola D, Grabar S for the FHDH (ANRS CO4) study team.

-->  Effect of early syphilis infection on plasma viral load and CD4 cell count in human immunodeficiency virus-infected men.
---->  Arch Intern Med 2012;172:1237-43.
        123  

Lang S, Mary-Krause M, Simon A, Partisani M, Gilquin J, Cotte L, Boccara F, Costagliola D, for the French Hospital Database on HIV-ANRS CO4.

-->  HIV replication and immune status are independent predictors of the risk of myocardial infarction in HIV-infected individuals.
---->  Clin Infect Dis 2012;55:600-7.
        124  

Lewden C, Bouteloup V, De Wit S, Sabin C, Mocroft A, Wasmuth JC, van Sighem A, Kirk O, Obel N, Panos G, Ghosn J, Dabis F, Mary-Krause M, Leport C, Perez-Hoyos S, Sobrino-Vegas P, Stephan C, Castagna A, Antinori A, d'Arminio Monforte A, Torti C, Mussini C, Isern V, Calmy A, Teira R, Egger M, Grarup J, Chêne G, Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord.

-->  All-cause mortality in treated HIV-infected adults with CD4 >500/mm3 compared with the general population: evidence from a large European observational cohort collaboration.
---->  Int J Epidemiol 2012;41:433-45.
        125  

Lodi S, Meyer L, Kelleher AD, Rosinska M, Ghosn J, Sannes M, Porter K.

-->  Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion.
---->  Arch Intern Med. 2012;172:1252-5.
        126  

May M, Hogg R, Justice A, Shepherd B, Costagliola D, Ledergerber B, Thiébaut R, Gill J, Kirk O, van Sighem A, Saag M, Navarro G, Sobrino P, Lampe F, Guest J, Crane H, D’Arminio Monforte A, Vehreschild JJ, Sterne J.

-->  Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics.
---->  Int J Epidemiol 2012;41:1807-20.
        127  

Murray M, Hogg R, Lima V, May M, Moore D, Abgrall S, Bruyand M, D'Arminio Monforte A, Tural C, Gill M, Harris R, Reiss P, Justice A, Kirk O, Saag M, Smith C, Weber R, Rockstroh J, Khaykin P, Sterne J; for the Antiretroviral Therapy Cohort Collaboration (ART-CC).

-->  The effect of injecting drug use history on disease progression and death among HIV-positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis.
---->  HIV Med. 2012;13:89-97.
        128  

Nakagawa F, Lodwick R, Costagliola D, van Sighem A, Torti C, Podzamczer D, Mocroft A, Ledergerber B, Dorrucci M, Cozzi-Lepri A, Jansen K, Masquelier B, García F, De Wit S, Stephan C, Niels Obel N, Fätkenheuer G, Castagna A, Sambatakou H, Mussini C, Ghosn J, Zangerle R, Duval X, Meyer L, Perez-Hoyos S, Fabre-Colin C, Kjaer J, Chene G, Grarup J, Phillips A.

-->  Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug experienced people with HIV in Europe.
---->  J Acquir Immune Defic Syndr 2012;59:294-9.
        129  

Pantazis N, Morrison C, Amornkul PN, Lewden C, Salata RA, Minga A, Chipato T, Jaffe H, Lakhi S, Karita E, Porter K, Meyer L, Touloumi G; on behalf of CASCADE Collaboration in EuroCoord and ANRS 1220 Primo-CI Study Group.

-->  Differences in HIV natural history among African and non-African seroconverters in Europe and seroconverters in sub-Saharan Africa.
---->  PLoS One. 2012;7(3):e32369.
        130  

Piketty C, Selinger-Leneman H, Bouvier AM, Belot A, Mary-Krause M, Duvivier C, Bonmarchand M, Abramowitz L, Costagliola D, Grabar S.

-->  Incidence of HIV-related anal cancer remains elevated despite long-term cART: results from the French Hospital Database on HIV.
---->  J Clin Oncol 2012;30:4360-6.
        131  

Young J, Psichogiou M, Meyer L, Ayayi S, Grabar S, Raffi F, Reiss P, Gazzard B, Sharland M, Gutierrez F, Obel, N, Kirk O, Miro JM, Furrer HJ, Castagna A, De Wit S, Munoz J, Kjaer J, Colin C, Grarup J, Chene G, Bucher H and The Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord.

-->  CD4 cell count and the risk of AIDS or death in HIV-infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE.
---->  PLoS Med. 2012;9(3):e1001194.
        132  

Zugna D, Geskus RB, De Stavola B, Rosinska M, Bartmeyer B, Boufassa F, Chaix ML, Babiker A, Porter K; the CASCADE Collaboration in EuroCoord.

-->  Time to virological failure, treatment change and interruption for individuals treated within 12 months of HIV seroconversion and in chronic infection.
---->  Antivir Ther. 2012;17:1039-1048.
Adresse Mentions légales Extranet Administration